Carolyn Discafani

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

Sridhar K. Rabindran, Carolyn Discafani, Edward Rosfjord et al. · Cancer Research · 2004 · 638 citations · Full text

Medicine, Oncology, Pharmacology +13

Combinatorial chemoprevention of intestinal neoplasia

C Torrance, Peta E. Jackson, Elizabeth A. Montgomery et al. · Nature Medicine · 2000 · 495 citations

Medicine, Cancer Biology, Oncology +14

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

Ker Yu, Lourdes Toral‐Barza, Carolyn Discafani et al. · Endocrine Related Cancer · 2001 · 418 citations · Full text

Medicine, Oncology, Pharmacology +17

Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity

Hwei‐Ru Tsou, Elsebe G. Overbeek-Klumpers, William Hallett et al. · Journal of Medicinal Chemistry · 2005 · 299 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity

Hwei‐Ru Tsou, Nellie Mamuya, Bernard D. Johnson et al. · Journal of Medicinal Chemistry · 2001 · 274 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15